1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C Cho,M-J Ahn,T.M Kim,C Kim,B.Y Shim,J-Y Han,A.E Drilon,H Lena,J.E Gomez,J.E Gray,M Awad,J Perez,M Navas,M Kaul,S Patel,B Gao,H Magnan,P Rietschel

doi:10.1016/j.annonc.2022.07.1296

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C Cho, M-J Ahn + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1296

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 3	License type: publisher-specific-oa

Affiliation: Sungkyunkwan University, Seoul National University Hospital, Georgetown University, St. Vincent's Hospital

#Unmet Need For Therapies #First In Human + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

There is an unmet need for therapies that improve outcomes for pts with MET-altered NSCLC. REGN5093 is a human bispecific MET antibody that induces internalisation and degradation of MET. We present safety, tolerability and preliminary antitumour activity of REGN5093 monotherapy in MET-altered aNSCLC.

Full Text